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The ‘antiflammin’ nonapeptides Pl and P2 [(1988) Nature 335, 726-7301 were synthesized and tested for inhibition of phospholipase 4 and release 
of prostaglandin E2 and leukotriene C, in stimulated cells in vitro, and in vivo for anti-inflammatory activity in rats with carrageenan-induced 
paw oedema. Porcine pancreatic phospholipase & was not inhibited at concentrations of OS-50 PM. Prostaglandin I$ and leukotriene C, release 
by mouse macrophages timulated with zymosan or ATP was not affected up to a concentration of 10 pM, nor was prostaghmdin release by 
interleukin l~stimulat~ mesangial cells and angiotensin H-stimulated smooth muscle cells. Both peptides exhibited no ~ti-in~ammato~ activity 
in carrageenan-induced rat paw oedema after topical (250 fig/paw) or systemic administration (1 or 4 mg/kg s.c.). These results do not support 
the claim of potent phospholipase b-inhibitory and anti-imflammatory activity of the ‘antiflamrnins’ Pl and P2 [l]. 
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1. INTRODUCTION 
Synthetic nona~ptides with amino acid sequences 
corresponding to areas of high sequence similarity of 
uteroglobin and Iipocortin I have been reported to be 
potent inhibitors of porcine pancreatic phospholipase 
AZ (PLA$ in vitro and to exhibit striking anti-inflam- 
matory effects in carrageen~-induced rat paw oedema 
in vivo [ 11. Because of the anti-inflammatory effect, the 
name ‘antiflammins’ has been proposed for these pep- 
tides [l]. 
The amino acid sequence of nonapeptide Pl, 
MQMKKVLDS, corresponds to the 9 C-terminal amino 
acids of c-helix 3 of uteroglobin, whereas nonapeptide 
P2, HDMNKVLDL, has the same sequence as the 
residues 246-254 of lipocortin I 111. Uteroglobin and 
lipo~o~in I belong to a family of structurally related 
proteins such as renocortin, calpactin and endonexin, 
which have a molecular mass of about 36 kDa, are in- 
ducible by glucocorticosteroids, show calcium-depen- 
dent binding to phospholipids and inhibit PLA2 (for 
review see [2]). The latter two properties appear to be 
intimately connected, as has been demonstrated recent- 
ly [3-51. 
It has been suggested that peptide Pl corresponds to 
an active site of uteroglobin responsible for its PLA2- 
inhibitor activity, and that an important ~ti-infl~- 
matory mechanism of the peptides Pl and P2 may be 
the inhibition of arachidonate release from the cell 
membrane by PLAz [ 11. However, van Binsbergen et al. 
recently synthesized the peptides Pl and P2 and could 
not detect any inhibitory activity on pancreatic PLAz in 
5 different kinetics assays [6]. In view of these unex- 
pected results and the obvious implications for the ‘an- 
tiflammin’ concept, we also synthesized the nonapep- 
tides Pl and P2 and attempted to reproduce both the 
PLA2-inhibitory effect in vitro and the anti-inflam- 
matory activity in vivo, under the experimental condi- 
tions described in the original publication by Miele et al. 
111. 
2. MATERIALS AND METHODS 
Cor~~n~e~ce uddrm: F. Miirki, Ciba-Geigy AG, R 1058.632, 
CH-4002 Basel, Switzerland 
Fmoc amino acids were purchased from Novabiochem AG 
(CH-4448 Lziufelfingen. Switzerland), porcine pancreatic PLAz (700 
Wmg) from Boehringer (M~nheim, FRG), l-stearoyl-2[1-‘4C]ara- 
chidonoyl-so-glycero-3-phosph~holine (58 mCi/mmol) and radio- 
immunoassay kits for PGEs and LTC4 from Amersham (UK), X- 
carrageenan and zymosan from Sigma (St. Louis, MO, USA) and 
angiotensin II from Calbiochem (Luzern, Switzerland). Human rec. 
interleukin-1.8 was kindly provided by the Biotechnology Department 
of Ciba-Geigy. Solvents and other reagents used were analytical 
grade. 
Abbreviations: DICD, diisopropylcarbodiimide; DMA, dimethyl- 
acetamide; FAB-MS, fast atom bombardment mass spectrometry; 
Fmoc, fluorenyl-methoxy-carbonyl; HOBt, I-hydroxy-benzotriazole; 
LTG, leukotriene C.+; MEM, modified Eagle’s medium; PGEs, pros- 
taglandin Es; PLAs, phosphoiipase AZ; TFA, trifluoroacetic acid 
2.1. Peptides 
Peptides Pl and P2 were synthesized using a standard Fmoc solid 
phase approach with an automated synthesizer 171. Side chain- 
protecting groups were test-butyloxy~arbonyl for Lys, rert-butyl for 
Asp, and trityl for His. Couplings were performed with DICD- 
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Table I 
Effect of the nonapeptides Pl and P2 on the activity of porcine pan- 
creatic PLAz 
Concentration IaM) PLAz activitv I% controll 
PI P2 
0.5 97.2 zt 2.6 101.8 * 17.6 
5 98.4 -+ 3.4 91.4 * 5.1 
15 98.1 f 2.7 90.7 f 0.7 
50 94.4 + 2.7 88.5 f 1.6 
Peptides were dissolved in 10 mM Tris/HCl, pH 7.5 with 1 mgfml fat- 
ty acid-free bovine serum albumin immediately before the assay 
Values are mean zt SE, n = 3 
preformed HOBt esters for 45 min at room temperature. Fmoc was 
cleaved with 20% piperidine in DMA (5 x 2 min). Yields were deter- 
mined by UV-monitoring of the Fmoc cleavage products (average of 
99% per coupling). Cleavage of the peptides from the p-alkoxy- 
benzylester polystyrene resin was done with a mixture of TFA/ 
water/ethanedithiol (93/5/2, v/v/v) twice for 5 min and complete 
removal of protecting groups was achieved by treatment with the 
same reagent for 1 h. The peptides were precipitated with peroxide- 
free diisopropylether/petrolether (l/l, v/v). 
2.1.1. Peptide 1 
The product was purified to homogeneity using HPLC (Nucleosil 
CDT, 20 x 250 mm, water -t CHrCN (0.1% TFA). TFA ions were ex- 
changed to acetate ions with an AG 1-X8 anion exchange resin from 
Bio-Rad. 
2.1.2. Peptide 2 
The crude product contained approximately 60% of the Met- 
sulfoxide peptide according to conventional reverse-phase HPLC and 
FAB-MS (observed mass: 1100). The sulfoxide derivative was reduced 
with 5 equiv. N&I (1 M in 95% TFA, 30 min, room tem~rature) and 
the salts were removed by size-exclusion chromatography (lOa 
AcOH, Biogel P2). The peptide still contained 20% of the sulfoxide 
derivative. There was no change in composition when both peptides 
were reanalyzed by HPLC after several weeks of storage in lyophiliz- 
ed form at - 20°C. P2 is significantly more sensitive to Met oxidation 
than PI. 
2.2. PLAz assay 
PLAr was assayed by the method described in Table I of [l], with 
the following modifications: The assay was scaled up to a volume of 
500 ~1; the enzyme concentration used (0.15 U/ml) was selected to 
produce 20-30% substrate hydrolysis, within the linear range of the 
assay (up to 45%); liberated [‘4C]arachidonic acid was extracted and 
separated as described [8]. This method avoided a possible interaction 
of the test peptides with arachidonic acid during TLC separation as 
used by Miele et al. [l]. 
2.3. Cell culture 
Primary cultures of peritoneal macrophages were established from 
resident cells of NMRI mice by lavage with Dulbecco’s modified 
Eagle’s medium (MEM) as described [9]. The cells were plated at 
4 x 104/well in 96-well plates in Dulbecco’s MEM with 0.05% (w/v) 
lactalbumin hydrotysate. 
Table II 
Effect of the nonapeptides Pl and P2 on PGEa and LTG release by 
stimulated cells 
Concentration Release (To control) 
@Ml Pl P2 
PGEz LTC4 PGEz LTC4 
Mouse macrophages, zymosan (100 +g/ml)a 
0.1 79 * 20 114 * 37 73 f 19 143 f 38 
1.0 73 It 10 142 rt: 36 72 f 18 137 f 46 
10.0 91 + 12 128 z!z 30 87 f 24 132 rf 32 
Mouse macrophages, ATP (50 PM)~ 
10.0 131 + 15 112f 6 122 f 14 138 f 27 
Mesangial cells, interleukin-1~ (1 nM)C 
0.05 136 f 31 not tested 
0.5 106 It 11 111 + 25 
5.0 97 f 12 89~ 9 
Smooth muscle cells, angiotensin II (108 nM}d 
0.01 75 f 27 71 f 11 
0.1 100 r 15 93 f 31 
1.0 113* 7 71 r~: 16 
10.0 125 f 20 79 4: 10 
Peptides were dissolved in culture medium immediately before the assay. 
Values are mean 2 SD, n=4 
a Release/lo6 cells: 
PGEz: basal 1.75 f 0.25 ng, stimulated 31.7 f 0.85 ng. 
LTC4: basal 0.08 + 0.06 ng, stimulated 155 + 29 ng. 
b Release/ 10’ cells: 
PGEz: basal 1.75 rt 0.25 ng, stimulated 4.70 + 1.40 ng. 
LTG: basal 0.08 4 0.06 ng, stimulated 1.47 & 0.60 ng. 
’ Release/lo6 cells: 
PGEz: basal 0.41 + 0.06 ng, stimulated 1.84 f 0.16 ng. 
d Release/ lo6 cells: 
PGEz: basal 50 & 10 pg. stimulated 250 f 20 pg. 
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paw volume (ml) 
3.5, 
0 2 4 6 h 
dose: !Jg per paw 
m Control $1 250 m P2 250 Dexa 0.25 
Fig. 1. Carrageenan-induced rat paw oedema, topical administration 
of test compounds. Vehicle control, n = 10; Pl, 250pg/paw n = 8; P2, 
25O,ug/paw n= 8; dexamethasone, 0.25 /cg/paw n = 10. Paw volumes 
are expressed as means f SD. Difference against controls: * PcO.05; 
**P<O.Ol; *+*P<o.a)l. 
Cultivation and characterization of rat renal mesangial cells was 
done as described [lo]. The cells were grown in RPM1 1640 medium 
in 24-well plates. 
Cultures of smooth muscle cells of rat aorta were prepared by an 
explant technique [I 11. The cells were grown in Dulbecco’s MEM in 
24-well plates. 
2.4. Incubation of cells and eicosanoid analysis 
The different celt types were pr~ncubat~ with the indicated con- 
centration of PI and P2 for 1 h. Thereafter, the macrophages were 
stimulated with (i) serum-treated zymosan (l@O~g/ml) or (ii) ATP (50 
PM) for 2 h [9]. The mesangial cells were stimulated with inter- 
leukin-lp (1 nM) for 24 h [lo] and the smooth muscle ceils were 
stimulated with angiotensin II (100 nM) for 1 h. All the incubations 
were performed in the continuous presence of the indicated amounts 
of PI and P2. After the stimulation period the medium was with- 
drawn and assayed for PGEr and LTG by radioimmunoassay [9,10]. 
2.5. Carrageenan-induced rat paw oedema /I.?] 
Hind paw oedema was induced in male Lewis rats (LEW/TIF, SPF, 
140-160 g body weight, 7-10 animals per group) by an intraplantar 
injection of h-carrageenan i to the right hind paw. The oedema was 
measured plethysmometrically before and up to 6 h after the car- 
rageenan injection. 
Topical administration of peptides Ill: intraplantar injection of 0.1 
ml of 1% carrageen~ in saline, followed after 30 s by peptide 1 or 2, 
25Opg/paw in 0.1 ml of 10 mM Tris/HCl, pH 8. Dexamethasone 0.25 
pg/paw served as a positive control. 
Systemic administration of peptides: intraplantar injection of 0.05 
ml of 2% carrageenan i  saline. Peptide 1 (1 mg/kg) or peptide 2 (4 
mg/kg) were injected subcutaneously 1 h before the irritant (5 ml/kg). 
They were dissolved imm~iately before injection in 10 mM 
Tris/HCl, pH 8. Indomethacin 3 mgfkg served as positive control. 
3. RESULTS 
The structures of the two nonapeptides used in this 
study were confirmed unequivocally by FAB-MS 
(observed masses of Pl and P2 1079 and 1084, respec- 
tively) and by Edman sequencing. 
The effect of the peptides on the activity of porcine 
pancreatic PLAz in vitro is shown in Table I. No inhibi- 
0 2 4 6 h 
dose: mglkg 8.~. 
m Control = Pl 1.0 fi%fi P2 4.0 - lndo 3.0 
Fig. 2. Carrageenan-induced rat paw oedema, systemic (sub- 
cutaneous) administration of test compounds. Vehicle control n = 10; 
Pl, 1 .O mg/kg n = 7; P2,4.0 mg/kg n = 10; indomethacin, 3.0 mg/kg 
n = 10. Paw volumes are expressed as means rt SD. Difference against 
controls: **P<O.Ol: ***P<O.GOl. 
tion was observed over the concentration range studied, 
i.e. from 0.5 to 50,~M. 
Effects on the release of PGEz and LTC4 by stim- 
ulated cells in vitro are summarized in Table II. Both 
peptides had no significant activity when studied at con- 
centrations up to 1OpM in zymosan- or ATP-stimulated 
mouse macrophages, in interleukin-lo-stimulated rat 
mesangial cells, or in angiotensin II-stimulated rat 
smooth muscle cells. 
Finally, anti-inflammatory activity was evaluated in 
the carrageenan-induced rat paw oedema model. When 
the peptides were administered topically at 250 pg/paw 
or systemically at a dose of 1 mg/kg S.C. (Pl) or 4 
mg/kg S.C. (P2), no anti-inflammatory effects were 
detected, whereas the reference compounds dex- 
amethasone and indomethacin significantly reduced 
oedema formation (Figs 1 and 2). 
4. DISCUSSION 
Two nonapeptides with amino acid sequences con- 
tained in the 36 kD proteins uteroglobin and lipocortin 
I were recently described by Miele et al. as potent in- 
hibitors of PLAz with striking anti-inflammatory ac- 
tivity in vivo [l]. The authors suggested that the 
oligopeptid~ Pl and P2 are able to mimic the biological 
activity of uteroglobin and lipocortin because they may 
represent an active site, or part of an active site, of the 
proteins. It has been proposed that uteroglobin, 
lipocortin and related proteins owe their anti- 
in~ammatory activity to a suppression of eicosanoid 
formation consequent o inhibition of PLAz [2,13-l 51. 
Inhibition of PLAz - determined in vitro with the en- 
zyme from porcine pancreas - is indeed the most fre- 
quently reported activity of lipoco~in-like proteins 
[2-5,15-221. However, in contrast to the earlier pro- 
posal by Hirata [23], it was recently convincingly 
173 
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demonstrated that inhibition of PLAz by lipocortin 
does not result from a direct interaction with the en- 
zyme, but rather from binding to the substrate. Inhibi- 
tion of PLAz is prominent at low, limiting substrate 
concentrations and disappears gradually when the 
substrate concentration is increased [3-51. It seems 
doubtful whether this mode of inhibition provides a 
physiolo~c~ly relevant basis for an anti-inflammatory 
effect in vivo (for a critical commentary on this subject 
see [24]). 
When we studied the ‘antiflammins’ Pl and P2 for 
possible inhibition of pancreatic PLA2 in vitro under 
the assay conditions of Miele et al. [l], we found them 
to be completely inactive, even at a 1000-fold higher 
concentration than that used by Miele et al. (Table I). 
Our results thus are in line with those of van Binsbergen 
et al. 161. These authors also tested the two nonapep- 
tides on porcine pancreatic PLAt and did not find in- 
hibition. Under a variety of assay conditions, e.g. vary- 
ing the type, the concentration and the physical struc- 
ture of the substrate, they could not obtain any evidence 
for an interaction of the peptides with either the enzyme 
or the substrate. 
We have also studied the peptides Pl and P2 in vitro 
using intact cells in culture, whose endogenous PLAz 
had been stimulated by different receptor-mediated 
ligands, i.e. zymosan, ATP, interleuki~ 1 and angioten- 
sin II. However, also under these more physiological 
assay conditions no inhibition of eicosanoid release - a 
process dependent on PLAz activity - was observed 
(Table II). While we are not aware of published data on 
effects of the ‘antiflammins’ Pl and P2 on PLAz activi- 
ty or eicosanoid release in intact cells, controversial 
results in cellular assays have been reported to lipocor- 
tins. Errasfa et al. observed inhibition of arachidonic 
acid release after A 23187 stimulation in mouse thy- 
mocytes [25] and guinea pig alveolar macrophages [26] 
by purified lipocortin from mice lung and thymocytes, 
respectively, whereas Northup et al. found human 
placental ipocortin I (calpactin II) to increase - rather 
than inhibit - arachidonic acid release in zymosan- 
stimulated mouse macrophages 1201. 
The striking anti-inflammatory activity of the 
nonapeptides Pl and P2 in the carrageenan oedema 
model in vivo reported by Miele et al. [l] is not sup- 
ported by our results (Figs 1 and 2). Topical administra- 
tion of the peptides at a dose comparable to the highest 
dose used by Miele et al. and systemic administration by 
the subcutaneous route were totally inactive during the 
early and late phase of the carrageenan oedema. On the 
other hand, two reference compounds - the glucocor- 
ticosteroid dexamethasone and the cyclooxygenase in- 
hibitor indometha~in - produced the expected signifi- 
cant oedema inhibition in this standard model for the 
evaluation of anti-inflammatory compounds. Ialenti et 
al. [27] recently also synthesized and tested two 
nonapeptides for anti-inflammatory activity. One of 
174 
them, designated as Antiflammin 1, which has the same 
amino acid sequence as peptide P2 111, caused a 
moderate inhibition of 30-35% only during the late 
phase of carrageenan-induced paw oedema after sub- 
cutaneous a~inistration of a high dose, 1 mg/kg. We 
were unable to confirm this result with a 4 times higher 
subcutaneous dose. 
Although the peptides used in our study had the cor- 
rect primary structure as confirmed by FAB-MS and 
Edman sequencing, we could not demonstrate PLAz in- 
hibition in vitro, nor mediator release inhibition from 
stimulated cells and anti-inflammatory activity in vivo. 
Therefore, the reasons for the discrepancy between the 
results of Miele et al. [l] and our findings together with 
those of van Binsbergen et al. [6] are not clear at present 
and need further clarification, Whether ‘~tiflammins’ 
is an appropriate name for these nonapeptides eems to 
be questionable at this time. 
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